At present about 18 million people worldwide suffer from Alzheimer disease, a neurodegenerative disorder which leads to dementia. The pharmaceuticals currently registered for the treatment of Alzheimer are only able to reduce symptoms marginally and delay progression of Alzheimer disease to a limited extent. The novel preventive target structure, the APP-AICD/ Fe65-PTB2 complex, offers a new chance for the development of a possible pharmaceutical for a causal treatment of Alzheimer disease.
Further information: PDF
Technologie-Lizenz-Büro (TLB) der Baden-Württembergischen Hochschulen GmbH
Phone: +49 (0)721/79 00 40
Dipl.-Biol. Marcus Lehnen, MBA
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
firstname.lastname@example.org | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
Graphene is up to the job
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
26.09.2017 | Life Sciences
26.09.2017 | Physics and Astronomy
26.09.2017 | Information Technology